Insilico Medicine Nominates First AI-Developed Drug Candidate in Abu Dhabi

Insilico Medicine has announced the nomination of its first generative artificial intelligence-driven preclinical drug candidate developed at its Abu Dhabi research and development center. The drug molecule, targeting a specific biological pathway for undisclosed indications, represents the first milestone for the company’s regional hub since its establishment in the UAE capital. AI-Powered Drug Discovery The candidate was identified using Insilico’s proprietary Pharma.AI platform, which utilizes deep learning models to predict how new molecules will interact with biological targets. By deploying generative chemistry and biology tools, researchers at the Abu Dhabi site reduced the time and cost typically associated with early-stage drug discovery. This nomination signifies that the molecule has met specific safety and efficacy benchmarks required to proceed to IND-enabling studies (Investigational New Drug). The Abu Dhabi R&D center, located in Masdar City, is currently the largest AI-driven biotechnology facility in the Middle East. It focuses on developing specialized algorithms and drug candidates for oncology, fibrosis, and aging-related diseases. The hub employs a team of…